D.A. Davidson & Co.
- SEC CIK
- 0001080107
- Latest filing
- Jul 24, 2026
VTGN holding history
Vistagen Therapeutics, Inc. in every 13F filed by D.A. Davidson & Co., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
VTGN overviewAll 13F holders of VTGNFull Q2 2026 holdings
- Shares (Q2 2023)
- 0
- Sold out in Q2 2023
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 9
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2023 | 0 | $0 | 0.0% | −2,217−100.0% | Sold outConverted for a 1-for-30 split | Holders |
| Q1 2023 | 66,500 | $8.29K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2022 | 66,500 | $6.85K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2022 | 66,500 | $10.0K | <0.1% | −47,500−41.7% | Reduced | Holders |
| Q2 2022 | 114,000 | $100.0K | <0.1% | −13,500−10.6% | Reduced | Holders |
| Q1 2022 | 127,500 | $158.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2021 | 127,500 | $249.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2021 | 127,500 | $349.0K | <0.1% | −4,000−3.0% | Reduced | Holders |
| Q2 2021 | 131,500 | $414.0K | <0.1% | −2,000−1.5% | Reduced | Holders |
| Q1 2021 | 133,500 | $284.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.